Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm

The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefit and serious safety risks.The drug company will effectively give up on marketing Aduhelm, which comes with unproven benefit and serious safety risks.Drugs (Pharmaceuticals), Aduhelm (Drug), Alzheimer’s Disease, Medicare, Appointments and Executive Changes, Biogen Inc, Food and Drug Administration, European Union, Vounatsos, MichelRead More